Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Arts. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

BALIAKAS Panagiotis AGATHANGELIDIS Andreas HADZIDIMITRIOU Anastasia SUTTON Lesley-Ann MINGA Eva TSANOUSA Athina SCARFO Lydia DAVIS Zadie YAN Xiao-Jie SHANAFELT Tait PLEVOVÁ Karla SANDBERG Yorick VOJDEMAN Fie Juhl BOUDJOGRA Myriam TZENOU Tatiana CHATZOULI Maria CHU Charles C. VERONESE Silvio GARDINER Anne MANSOURI Larry SMEDBY Karin E. PEDERSEN Lone Bredo MORENO Denis VAN LOM Kirsten GIUDICELLI Véronique SKUHROVÁ FRANCOVÁ Hana NGUYEN-KHAC Florence PANAGIOTIDIS Panagiotis JULIUSSON Gunnar ANGELIS Lefteris ANAGNOSTOPOULOS Achilles LEFRANC Marie-Paule FACCO Monica TRENTIN Livio CATHERWOOD Mark MONTILLO Marco GEISLER Christian H. LANGERAK Anton W. POSPÍŠILOVÁ Šárka CHIORAZZI Nicholas OSCIER David JELINEK Diane F. DARZENTAS Nikos BELESSI Chrysoula DAVI Frederic GHIA Paolo ROSENQUIST Richard STAMATOPOULOS Kostas

Year of publication 2015
Type Article in Periodical
Magazine / Source Blood
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.bloodjournal.org/content/125/5/856?sso-checked=true
Doi http://dx.doi.org/10.1182/blood-2014-09-600874
Field Oncology and hematology
Keywords B-CELL RECEPTORS; GENE MUTATIONAL STATUS; CD38 EXPRESSION; PATHOGENETIC IMPLICATIONS; GENOMIC ABERRATIONS; PATTERNS; SUBSETS; SELECTION; DISEASE
Attached files
Description An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset # 2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset # 2. Within subset # 2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset # 2/IGHV3-21 was enriched for IGHV-unmutated cases (P =.002). Subset # 2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset # 2/IGHV3-21 (22 vs 60 months, P =.001). No such difference was observed between non-subset # 2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset # 2 emerges as uniformly aggressive, contrasting non-subset # 2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.